EC[ON]OMY

How Kazakhstan Can Save Billions with Generics and Biosimilars

Generics and biosimilars aren’t just cheaper copies. They’re a strategic tool that can significantly cut healthcare costs. In 2023 alone they saved the U.S. healthcare system $445 billion. Kazakhstan has the potential to achieve similar success—if the right policies are put in place.

According to the Association for Accessible Medicines (AAM), generics and biosimilars make up 91% of prescriptions in the U.S. but only 18% of total drug spending. Their share of total healthcare expenditure is less than 1%—a result of healthy competition and effective regulation.

Biosimilars alone saved $36 billion since 2015, including $12.4 billion in 2023.

Top savings areas:

•  Heart disease — $118.1 billion

•  Mental health — $76.4 billion

•  Diabetes — $61 billion

In 2024 imported drugs accounted for 86.6% of Kazakhstan’s pharmaceutical market by value and 73.8% by volume. However, there’s a positive shift: domestic production is growing, especially in the affordable segment—drugs priced under 3,000 tenge represent 97.4% of local production by volume and 75.8% by value.

The hospital segment remains heavily import-reliant: 80.4% of spending goes to foreign medicines (71.3% by volume). Still, local drugs are gaining ground—28.7% by volume.

This means two things:

1. Kazakhstan pays a premium for imports.

2. The domestic pharmaceutical sector is ready to expand, given proper support.

When the patent for an original drug expires, generic manufacturers enter the market. The absence of costs for preclinical studies, Phase II and III clinical trials, and marketing allows them to reduce prices by 30–80%. A similar pattern applies to biosimilars, which are priced 15–40% lower than the originals and typically bring down the price of originator products by an average of 33%.

For Kazakhstan this means:

•  A chance to replace expensive imports with affordable alternatives

•  A way to foster local competition and grow domestic production

•  A potential export market in neighboring regions

What’s holding the market back?

Even in the U.S. medicine shortages are a concern. Over 60% are linked to ultra-low prices (under $1), which make production unprofitable. For Kazakhstan, it’s a warning: without fair margins, manufacturers may exit the market.

Another challenge is administration:

•  In the U.S., over half of generics aren’t listed in Medicare’s preferred drug tiers, making them less accessible.

•  In Kazakhstan, reimbursement policies and pricing regulations could pose similar barriers.

Biosimilars are most effective for chronic, serious diseases like cancer, rheumatoid arthritis, and blood disorders. In Kazakhstan, where cancer treatment is a major burden on families and public funds, biosimilars could bring real relief.

What Kazakhstan needs

1 Develop local production: Support R&D, ensure GMP compliance, attract investment.

2. Regulatory reform: eliminating bureaucratic barriers, ensuring a competitive environment, and promoting transparent pricing.

3. Revise reimbursement systems: Include generics and biosimilars in procurement lists.

4. Educate doctors and patients: Break the myth that cheap means ineffective.

If Kazakhstan builds a supportive environment and follows the U.S. model, it could save billions of tenge annually just from wider biosimilar use.

According to AAM, the U.S. could save another $42.9 billion by 2027 with better biosimilar adoption. For Kazakhstan, this means:

•  Pricing reform

  • To have a mature inspection system and enhance trust in national expertise

•  Incentives across the supply chain—from manufacturers to prescribers

Generics and biosimilars are not just about saving money. They’re a foundation for a stronger, more accessible healthcare system. Kazakhstan faces a choice: keep relying on expensive imports or invest in its own pharmaceutical future. The issue isn’t cost—it’s strategy.

 
Prepared by: Guldariya Manakpaeva, Executive Director of the
“PharmMedIndustry Kazakhstan” Association, specifically for http://www.economyKZ.org

Scroll to Top